Treatment progress of peripheral T-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 71-73, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-882242
ABSTRACT
Peripheral T-cell lymphoma (PTCL) is a relatively common subtype of non-Hodgkin lymphoma in China. PTCL is clinically highly aggressive, and it progresses rapidly. The current treatment methods are ineffective and the overall prognosis is poor. The 62nd American Society of Hematology Annual Meeting reported on the progress of PTCL molecular targeted therapy and immunotherapy, including programmed death receptor 1/programmed death receptor ligand 1 antibodies, JAK inhibitors, brentuximab vedotin, etc. These novel drugs bring a better prospect for patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS